The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
Age range
12 Years – 17 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Nemolizumab Serum Concentrations at Week 1-2
Timeframe: At week 1-2
Nemolizumab Serum Concentrations at Week 4
Timeframe: At week 4
Nemolizumab Serum Concentrations at Week 8
Timeframe: At week 8
Nemolizumab Serum Concentrations at Week 12
Timeframe: At week 12
Nemolizumab Serum Concentrations at Week 16
Timeframe: At week 16
Nemolizumab Serum Concentrations at Week 24
Timeframe: At week 24
Apparent Clearance After Extravascular Administration (Cl/F) of Nemolizumab
Timeframe: Baseline to week 24
Apparent Volume of Distribution After Extravascular Administration (Vd/F) of Nemolizumab
Timeframe: Baseline to week 24
Population Lag Time (Tlag)
Timeframe: Baseline to week 24
First Order Constant of Absorption (ka)
Timeframe: Baseline to week 24
Maximum Observed Serum Concentration (Cmax) of Nemolizumab
Timeframe: Baseline to week 12
Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab
Timeframe: Baseline to week 12
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 4
Timeframe: At week 4
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 8
Timeframe: At week 8
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 12
Timeframe: At week 12
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 16
Timeframe: At week 16
Area Under the Serum Concentration-Time Curve From Zero to 4 Week Post-dose (AUC0-4w)
Timeframe: Pre-dose through 4 weeks post-dose
Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)
Timeframe: Pre-dose through 8 weeks post-dose
Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)
Timeframe: Pre-dose through 12 week post-dose
Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)
Timeframe: Pre-dose through 16 weeks post-dose
Apparent Terminal Half-life (t1/2)
Timeframe: Baseline to week 24
Number of Participants With Treatment-Related Positive Anti-Drug Antibodies (ADA) in Serum at Week 4
Timeframe: At week 4
Number of Participants With Neutralizing Antibodies
Timeframe: Baseline up to Week 24
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Adverse Event of Special Interests (AESI) and Serious Adverse Events (SAEs)
Timeframe: Baseline through week 24
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 1-2
Timeframe: At week 1-2
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 4
Timeframe: At week 4
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 8
Timeframe: At week 8
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 12
Timeframe: At week 12
Number of Participants With Clinically Significant Abnormalities in Physical Examination (PE) Findings
Timeframe: Baseline up to Week 24
Number of Participants With Clinically Significant Abnormalities in Laboratory Values
Timeframe: Baseline up to Week 24
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings at Week 16
Timeframe: At week 16
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Timeframe: Baseline up to Week 24
Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% of Predicted Value at Week 1-2
Timeframe: At week 1-2
Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% Predicted Value at Week 4
Timeframe: At week 4